Vaccines Technologies

ARTES offers a range of vaccine producing cell lines and processes for out-licensing and technology transfer. All listed cell lines are based on our safe and high yield yeast expression system Hansenula polymorpha.



Avian Flupre-clinical PoC; based on METAVAX® VLP plat­form highly immuno­genic, adjuvant-free; cell line and process avail­able
Hepati­tis Blicensed world­wide; new tech­nol­ogy with improved yield; RCB, USP, DSP IPC/QC protocols avail­able
HPV
(L1-6; -11; -16; -18)		RCB, USP, DSP IPC/QC protocols for the dif­fer­ent serotypes avail­able
Covid
(SARS-CoV-2 receptor binding domain (RBD))		pre-clinical PoC; based on METAVAX® VLP plat­form highly immuno­genic, adjuvant-free; cell line and process avail­able


To obtain a quote, please contact us at info(at)artes-biotechnology.com indicating name of the vaccine of interest to you. We will revert to you with a dedicated offer specifying delivery times and costs.

Enzymes

ARTES offers a range of enzyme producing cell lines and processes for out-licensing and technology transfer. All listed cell lines are based on our safe and high yield yeast expression systems Hansenula polymorpha or E.coli.



NameDonor organismEC number
Phy­taseAspergillus ficuum3.1.3.8
CalB LipaseCandida antarctica3.1.1.3
Endoglu­canase IITrichoderma reesei3.2.1.4
Algi­nate EpimeraseAzotobacter vinelandii5.1.3
D-Galactose-1-DehydrogenaseXanthomonas campestris1.1.1.48
3-alpha-Hydroxysteroid-DehydrogenasePseudomonas spec.1.1.1.50
Cel­lobio­hy­dro­lase ITrichoderma viride3.2.1.91
Cel­lobio­hy­dro­lase IITrichoderma reesei3.2.1.91
Endoglu­canase ITrichoderma reesei3.2.1.4
alpha-MannosidaseAspergillus saitoi3.2.1.113
alpha-AmylaseSchwanniomyces occidentalis3.2.1.1
endo-ß-1,4-XylanasePenicillium simplicissimum3.2.1.8
EndoHStreptomyces plicatus3.2.1.96


To obtain a quote, please contact us at info(at)artes-biotechnology.com indicating name of the cell line of interest to you. We will revert to you with a dedicated offer specifying delivery times and costs.

Biosimilars Technologies

ARTES offers a range of biosimilar producing cell lines and processes for out-licensing and technology transfer. The listed cell lines are based on yeast, E. coli or mammalian expression system.



Inter­feron alpha2ayeast; mar­keted in Mena region; new tech­nol­ogy with improved yield; RCB, USP, DSP IPC/QC protocols available; PEGy­lated process available
Inter­feron alpha2byeast; licensed to India; RCB, USP, DSP IPC/QC protocols available; PEGy­lated process available
Hirudinyeast; mar­keted in Mena region; new tech­nol­ogy with improved yield avail­able, MCB/WCB, USP, DSP, IPC/QC protocols available
Bivalirudinyeast; licensed to Egypt; RCB, USP, DSP IPC/QC protocols available
Full length factor VIIImammalian; MCB/WCB, USP, DSP IPC/QC protocols available
Insulinyeast; cell line and process as mar­keted in India; RCB, USP, DSP IPC/QC protocols available
Detemiryeast; RCB, USP protocols available; IPC/QC & DSP devel­op­ment time: approx. 6 months
Liraglutideyeast; RCB, USP protocols available; IPC/QC & DSP devel­op­ment time: approx. 6 months
Lisproyeast; proof-of-concept for expres­sion achieved; cell line & process to be devel­oped; devel­op­ment time: approx. 9 months
Glarginyeast; proof-of-concept for expres­sion achieved; cell line & process to be devel­oped; devel­op­ment time: approx. 9 months
Teduglutideyeast; cell line & process to be devel­oped; devel­op­ment time: approx. 9 months
Aspartyeast; cell line & process to be devel­oped; devel­op­ment time: approx. 9 months
G-CSFE. coli; RCB, USP protocols available; IPC/QC & DSP development time: approx. 6 months
hGrowth Hor­moneyeast; RCB, USP protocols available, IPC/QC & DSP devel­op­ment time: approx. 6 months
PTHyeast; MCB/WCB, USP; DSP IPC/QC protocols available
Follicle stimulating Hormonemammalian; MCB/WCB, USP, DSP IPC/QC protocols available
Staphy­lok­i­naseyeast; RCB, USP, DSP IPC/QC protocols avail­able
HSAyeast; RCB, USP protocols available; IPC/QC & DSP development time: approx. 6 months


To obtain a quote, please con­tact us at info(at)artes-biotechnology.com indi­cat­ing name of the biosimilar process of interest to you. We will revert to you with a ded­i­cated offer spec­i­fy­ing deliv­ery times and costs.